Safety of measles, mumps, and rubella vaccine in adolescents and adults in the vaccine safety Datalink
© 2023 The Author(s)..
Background: Measles, mumps, and rubella vaccine (MMR) is routinely administered to children; however, adolescents and adults may receive MMR for various reasons. Safety studies in adolescents and adults are limited. We report on safety of MMR in this age group in the Vaccine Safety Datalink.
Methods: We included adolescents (aged 9-17 years) and adults (aged ≥ 18 years) who received ≥ 1 dose of MMR from January 1, 2010-December 31, 2018. Pre-specified outcomes were identified by diagnosis codes. Clinically serious outcomes included anaphylaxis, encephalitis/myelitis, Guillain-Barré syndrome, immune thrombocytopenia, meningitis, and seizure. Non-serious outcomes were allergic reaction, arthropathy, fever, injection site reaction, lymphadenopathy, non-specific reaction, parotitis, rash, and syncope. All serious outcomes underwent medical record review. Outcome-specific incidence was calculated in pre-defined post-vaccination windows. A self-controlled risk interval design was used to determine the relative risk of each outcome in a risk window after vaccination compared to a more distal control window.
Results: During the study period, 276,327 MMR doses were administered to adolescents and adults. Mean age of vaccinees was 34.8 years; 65.8 % were female; 53.2 % of doses were administered simultaneously with ≥ 1 other vaccine. Serious outcomes were rare, with incidence ≤ 6 per 100,000 doses for each outcome assessed, and none had a significant elevation in incidence during the risk window compared to the control window. Incidence of non-serious outcomes per 100,000 doses ranged from 3.4 for parotitis to 263.0 for arthropathy. Other common outcomes included injection site reaction and rash (157.0 and 112.9 per 100,000 doses, respectively). Significantly more outcomes were observed during the risk window compared to the control window for all non-serious outcomes except parotitis. Some variability was observed by sex and age group.
Conclusion: Serious outcomes after MMR are rare in adolescents and adults, but vaccinees should be counseled regarding anticipated local and systemic non-serious adverse events.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Vaccine: X - 13(2023) vom: 09. Apr., Seite 100268 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hanson, Kayla E [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Revised 24.02.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.jvacx.2023.100268 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353208590 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353208590 | ||
| 003 | DE-627 | ||
| 005 | 20231226055459.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jvacx.2023.100268 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1177.xml |
| 035 | |a (DE-627)NLM353208590 | ||
| 035 | |a (NLM)36814595 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hanson, Kayla E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety of measles, mumps, and rubella vaccine in adolescents and adults in the vaccine safety Datalink |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 24.02.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 The Author(s). | ||
| 520 | |a Background: Measles, mumps, and rubella vaccine (MMR) is routinely administered to children; however, adolescents and adults may receive MMR for various reasons. Safety studies in adolescents and adults are limited. We report on safety of MMR in this age group in the Vaccine Safety Datalink | ||
| 520 | |a Methods: We included adolescents (aged 9-17 years) and adults (aged ≥ 18 years) who received ≥ 1 dose of MMR from January 1, 2010-December 31, 2018. Pre-specified outcomes were identified by diagnosis codes. Clinically serious outcomes included anaphylaxis, encephalitis/myelitis, Guillain-Barré syndrome, immune thrombocytopenia, meningitis, and seizure. Non-serious outcomes were allergic reaction, arthropathy, fever, injection site reaction, lymphadenopathy, non-specific reaction, parotitis, rash, and syncope. All serious outcomes underwent medical record review. Outcome-specific incidence was calculated in pre-defined post-vaccination windows. A self-controlled risk interval design was used to determine the relative risk of each outcome in a risk window after vaccination compared to a more distal control window | ||
| 520 | |a Results: During the study period, 276,327 MMR doses were administered to adolescents and adults. Mean age of vaccinees was 34.8 years; 65.8 % were female; 53.2 % of doses were administered simultaneously with ≥ 1 other vaccine. Serious outcomes were rare, with incidence ≤ 6 per 100,000 doses for each outcome assessed, and none had a significant elevation in incidence during the risk window compared to the control window. Incidence of non-serious outcomes per 100,000 doses ranged from 3.4 for parotitis to 263.0 for arthropathy. Other common outcomes included injection site reaction and rash (157.0 and 112.9 per 100,000 doses, respectively). Significantly more outcomes were observed during the risk window compared to the control window for all non-serious outcomes except parotitis. Some variability was observed by sex and age group | ||
| 520 | |a Conclusion: Serious outcomes after MMR are rare in adolescents and adults, but vaccinees should be counseled regarding anticipated local and systemic non-serious adverse events | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ACIP, Advisory Committee on Immunization Practices | |
| 650 | 4 | |a Adolescents | |
| 650 | 4 | |a Adults | |
| 650 | 4 | |a CDC, Centers for Disease Control and Prevention | |
| 650 | 4 | |a CI, confidence interval | |
| 650 | 4 | |a ED, emergency department | |
| 650 | 4 | |a GBS, Guillain-Barré syndrome | |
| 650 | 4 | |a ICD-10-CM, International Classification of Diseases, 10th Revision, Clinical Modification | |
| 650 | 4 | |a ICD-9-CM, International Classification of Diseases, 9th Revision, Clinical Modification | |
| 650 | 4 | |a IQR, interquartile range | |
| 650 | 4 | |a ITP, immune thrombocytopenia | |
| 650 | 4 | |a MMR | |
| 650 | 4 | |a MMR, measles, mumps, and rubella vaccine | |
| 650 | 4 | |a MMRV, measles, mumps, rubella, and varicella vaccine | |
| 650 | 4 | |a RR, relative risk | |
| 650 | 4 | |a SCRI, self-controlled risk interval | |
| 650 | 4 | |a Safety | |
| 650 | 4 | |a VAERS, Vaccine Adverse Event Reporting System | |
| 650 | 4 | |a VSD, Vaccine Safety Datalink | |
| 650 | 4 | |a Vaccine | |
| 700 | 1 | |a Marin, Mona |e verfasserin |4 aut | |
| 700 | 1 | |a Daley, Matthew F |e verfasserin |4 aut | |
| 700 | 1 | |a Groom, Holly C |e verfasserin |4 aut | |
| 700 | 1 | |a Jackson, Lisa A |e verfasserin |4 aut | |
| 700 | 1 | |a Sy, Lina S |e verfasserin |4 aut | |
| 700 | 1 | |a Klein, Nicola P |e verfasserin |4 aut | |
| 700 | 1 | |a DeSilva, Malini B |e verfasserin |4 aut | |
| 700 | 1 | |a Panagiotakopoulos, Lakshmi |e verfasserin |4 aut | |
| 700 | 1 | |a Weintraub, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Belongia, Edward A |e verfasserin |4 aut | |
| 700 | 1 | |a McLean, Huong Q |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Vaccine: X |d 2019 |g 13(2023) vom: 09. Apr., Seite 100268 |w (DE-627)NLM299955931 |x 2590-1362 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2023 |g day:09 |g month:04 |g pages:100268 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jvacx.2023.100268 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2023 |b 09 |c 04 |h 100268 | ||